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In studies of acute hepatitis C virus (HCV) infection, the early host immune response is one of the
determinants of viral persistence. The class I human leukocyte antigens (HLA), which present foreign antigen
to cytolytic T cells, are integral components of this response. We hypothesized that the highly polymorphic HLA
genes affect the outcome of an HCV infection. To test this hypothesis, we molecularly typed 231 persons with
well-documented clearance of an HCV infection and 444 matched persistently infected persons. HLA-A*1101
(odds ratio [OR], 0.49; 95% confidence interval [95% CI], 0.27 to 0.89), HLA-B*57 (OR, 0.62; 95% CI, 0.39 to
1.00), and HLA-Cw*0102 (OR, 0.43; 95% CI, 0.21 to 0.89) were associated with viral clearance, whereas
HLA-A*2301 (OR, 1.78; 95% CI, 1.01 to 3.11) and HLA-Cw*04 (OR, 1.78; 95% CI, 1.21 to 2.59) were associated
with viral persistence. HLA-Cw*04 is in strong linkage disequilibrium with HLA-B*53 and HLA-B*35, but only
HLA-B*53 (OR, 1.70; 95% CI, 0.95 to 3.06) and the Cw*04-B*53 haplotype (OR, 1.76; 95% CI, 0.94 to 3.26) were
weakly associated with viral persistence. HLA-B*53 has similar, but not necessarily identical, binding speci-
ficity to some HLA-B*35 subtypes (B*35-Px group). The association with the B*35-Px group was less strong
than with HLA-B*53 alone. The association of HLA-Cw*04 with HCV persistence was codominant (two copies
of the gene were more strongly associated with persistence than one copy). However, HLA-Cw*04 was not
associated with HCV RNA levels among the persistently infected individuals. Since Cw*04 is a ligand for the
killer immunoglobulin-like receptors on natural killer cells, these cells may be involved in recovery from HCV
infection. Further investigation is needed to understand the relationship between class I alleles and HCV
clearance.
Hepatitis C virus (HCV) is an important blood-borne patho-
gen that is eliminated from the host in approximately 15% of
acutely infected individuals while persisting in the remaining
85% of acutely infected individuals (1, 26). The factors in-
volved in viral clearance are not understood, but many studies
suggest host differences are critical. Of 704 Irish women who
were accidentally infected with the same viral inoculum (con-
taminated immunoglobulin D antibody), 314 (45%) cleared
their infection (13). Likewise, 43% of 152 German women
cleared their infection after being exposed to the same con-
taminated lot of immunoglobulin D antibody (16). Since the
women in their respective studies received the same virus, viral
diversity cannot account for the dichotomy in outcome, rather
differences in host response were likely the determining factor.
Another study found marked differences in the frequency of
viral clearance in Caucasians and African-Americans (21). The
breadth and vigor of the host cellular immune response cor-
related with viral clearance in a study of six chimpanzees (6).
Similarly, studies in humans have shown that a stronger poly-
clonal cytotoxic T lymphocyte (CTL) response is associated
with viral clearance (18).
The class I and class II human leukocyte antigens (HLA) are
central to the host immune response and thus are ideal candi-
date genes to investigate for associations with HCV outcomes.
Class I and class II HLA are encoded by the most polymorphic
genes known and present antigen to CD8 cytotoxic T cells
and CD4 helper T cells, respectively. Polymorphisms in the
peptide binding regions of these molecules determine anti-
genic specificities and the strength of the immune response to
a given pathogen. Certain HLA alleles have been shown to
influence the outcome of other chronic viral infections (12, 19,
23), and a few recent studies examined class II HLA alleles in
the context of HCV clearance (3, 20, 22, 25). Given the im-
portance of the cellular immune response in HCV infection, it
is reasonable to postulate that certain HLA class I molecules
may present HCV epitopes to cytotoxic T cells, resulting in a
protective immune response, whereas other types may partic-
ipate less efficiently in clearance of the virus. To date, this
hypothesis has not been investigated; thus, using three distinct
cohorts of individuals, we examined whether particular HLA
class I alleles are predisposing factors to either HCV clearance
or persistence.
MATERIALS AND METHODS
Study participants. Subjects in this study were participants in one of three
studies: (i) AIDS Link to Intravenous Experience (ALIVE) study, which is an
ongoing study of 2,921 injection drug users enrolled in Baltimore, Md., from
February 1988 to March 1989, as previously described (27); (ii) Multicenter
Hemophilia Cohort Study (MHCS), which is a prospectively followed cohort of
patients with hemophilia, von Willebrand’s disease, or a related coagulation
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disorder from 16 comprehensive hemophilia treatment centers enrolled between
1982 and 1996, as previously described (10); and (iii) Hemophilia Growth and
Development Study (HGDS), which is a continuing study of 333 children and
adolescents with hemophilia enrolled between March 1989 and May 1990, as
previously described (11). A nested case control design was used. Individual
cases had cleared viremia as demonstrated by an inability to detect HCV RNA
in at least two serum samples that were drawn a minimum of 6 months apart.
Prior infection was substantiated by detection of HCV antibody (anti-HCV).
Persistently infected control individuals were selected from the same cohort and
had anti-HCV and HCV RNA in serum for a minimum of 6 months. Controls
were matched 2:1 to individuals in the same cohort by human immunodeficiency
virus (HIV) status, gender, geographic location (if applicable), and race. These
factors were chosen because HIV status and race are determinants of viral
clearance in the ALIVE cohort (21). Informed consent was obtained from all
patients, and the study was approved by the Institutional Review Board at Johns
Hopkins University, the National Cancer Institute, and from the individual study
cohorts.
Serologic testing. Subjects who tested positive for anti-HCV by second-gen-
eration Ortho HCV 2.0 enzyme immunoassay (EIA) (Ortho Diagnostic Systems,
Raritan, N.J.) had two samples, separated by a minimum of 6 months, assessed
for HCV RNA by a branched DNA (bDNA) assay (Quantiplex HCV RNA 2.0
assay; Chiron Corporation, Emeryville, Calif.). Subjects with two samples below
the limit of detection by the bDNA assay had at least one of the two samples
retested with the HCV COBAS AMPLICOR system (COBAS AMPLICOR
HCV; Roche Diagnostics, Branchburg, N.J.), and their antibody status was
confirmed by a recombinant immunoblot assay (RIBA 3.0) (Chiron Corpora-
tion). Only subjects with a negative HCV RNA result confirmed by COBAS
testing were considered to have cleared the viral infection. Subjects with two
positive bDNA assay results were eligible to be matched to the HCV clearance
subjects as controls.
HIV type 1 (HIV-1) testing was done by EIA, and positive results for speci-
mens were confirmed by Western blotting as previously reported (10, 11, 27).
Hepatitis B surface antigen (HBsAg) status was determined by EIA (AUS-
ZYME; Abbott Laboratories, Abbott Park, Ill.). All assays were performed
according to the manufacturer’s specifications except for COBAS testing of
samples that contained heparin. These samples were treated with heparinase
prior to COBAS testing using a Roche protocol for preparation of heparinized
plasma samples. All samples used for testing had been stored at 70°C after
processing and had not been previously used for other assays.
HLA typing. An Epstein-Barr virus-transformed cell line was established for
each subject, and DNA was extracted from these cell lines by phenol-chloroform
extraction. High-resolution (allele level) HLA genotyping was performed using
the standard sequence-specific oligonucleotide (SSO) probe typing protocols
developed by the 13th International Histocompatibility Workshop (http://www
.ihwg.org/protocols/protocol.htm). HLA-A, -B, and -C genes were amplified us-
ing locus-specific PCR primers flanking exons 2 and 3, the polymorphic segments
of the class I genes. The 1-kb PCR products were blotted on nylon membranes
and hybridized with a panel of SSO probes. HLA alleles were assigned to the
individuals by the reaction patterns of the SSO probes based on the known HLA
sequences. The entire exons 2 and 3 were sequenced in samples with ambiguous
SSO typing results.
Statistical analysis. All statistical analyses were performed using SAS version
6.12 (SAS Institute, Cary, N.C.). The frequencies of HLA class I alleles and
homozygosity were compared between the individuals who cleared HCV infec-
tion and those who had a persistent infection. Homozygosity was defined in two
ways for the purposes of analysis: (i) having identical alleles at HLA-A and -B or
-C or (ii) having identical alleles at two or three of these HLA loci. Odds ratios
(OR) were determined by conditional logistic regression and reflect the likeli-
hood of being persistently infected with HCV if carrying a specific allele.
RESULTS
We analyzed HLA class I alleles for 231 individuals with
HCV clearance and 444 matched individuals who were persis-
tently HCV infected. There were 18 persons with HCV clear-
ance for whom only one matching persistently infected indi-
vidual was identified. Although age was not a matching
criterion, the mean ages in the clearance and persistently in-
fected groups were similar at 25 and 27 years, respectively
(Table 1). The two groups were not different in terms of our
matching criteria, including race, sex, and HIV status. How-
ever, those with viral clearance were more likely to be HBsAg
positive and thus persistently infected with hepatitis B virus
(P  0.0001).
Viral clearance. Three alleles, HLA-A*1101 (OR, 0.49; 95%
confidence interval [95% CI], 0.27 to 0.89), HLA-B*57 (OR,
0.62; 95% CI, 0.39 to 1.00), and HLA-Cw*0102 (OR, 0.43; 95%
CI, 0.21 to 0.89) were associated with viral clearance (Table 2).
HLA-B*5701 and HLA-B*5703 accounted for over 90% of the
HLA-B*57 alleles, and of these two alleles, only HLA-B*5701
was weakly associated with clearance (OR, 0.68; 95% CI, 0.34
to 1.36). When stratified by race, the HLA-A*1101 and HLA-
B*57 associations were consistent in African-Americans and
Caucasians. Although a strong HLA-Cw*0102 association with
viral clearance was observed in Caucasians (OR, 0.26; 95% CI,
0.11 to 0.64), this was not seen in African-Americans (OR,
1.56; 95% CI, 0.15 to 16.6). A multivariate model including
HBsAg status did not modify the relationships for any of these
alleles. None of these alleles formed a haplotype with class II
alleles that have been associated with viral clearance in this
cohort (20).
TABLE 1. Characteristics of the subjects with cleared and
persistent HCV infection
Characteristic
Subjects with HCV infection
Cleared
(n  231)
Persistent
(n  444)
Mean age (yr) 25.1 27.3
Gender (% male) 86 86
Race (%)
Caucasian 51 49
African-American 40 41
Other 9 10
HBsAg status (% positive) 14.3a 4.8
HIV status (% positive) 34 35
a Significantly different from the value obtained for subjects with persistent
HCV infection (P  0.0001).
TABLE 2. HLA class I alleles that are predisposing factors to
clearance of HCV infection, stratified by ethnic group
Group and
HLA allelea
Frequency of
clearance (%)
Frequency of
persistence (%) OR (95% CI)
All participants
A*1101 5.3 2.8 0.49 (0.27–0.89)
B*57 7.3 4.6 0.62 (0.39–1.00)
Cw*0102 3.7 1.7 0.43 (0.21–0.89)
Caucasians
A*1101 7.0 4.1 0.55 (0.26–1.17)
B*57 6.1 3.9 0.56 (0.26–1.18)
Cw*0102 6.5 1.8 0.26 (0.11–0.64)
African-Americans
A*1101 2.1 1.1 0.50 (0.13–2.00)
B*57 9.1 5.2 0.58 (0.30–1.13)
Cw*0102 0.5 0.8 1.56 (0.15–16.6)
a The numbers of alleles examined (n) (double the number of persons) were as
follows: for all participants, n  462 for frequency of clearance and 888 for
frequency of persistence; for Caucasians, n  234 for clearance and 438 for
persistence; for African-Americans, n  186 for clearance and 362 for persis-
tence.
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Viral persistence. HLA-Cw*04 (OR, 1.78; 95% CI, 1.23 to
2.59) and HLA-A*2301 (OR, 1.78; 95% CI, 1.01 to 3.11) were
associated with HCV persistence (Table 3). The association
with HLA-A*2301 was observed in African-Americans (OR,
2.24; 95% CI, 1.10 to 4.57), whereas the association with HLA-
Cw*04 was observed in both African-Americans (OR, 1.69;
95% CI, 1.02 to 2.79) and Caucasians (OR, 1.69; 95% CI, 0.91
to 3.15). A multivariate model including HBsAg status did not
alter the relationship for either allele. Neither of these alleles
formed a haplotype with class II alleles that have been associ-
ated with persistence in this cohort (20). HLA-Cw*04 had a
fairly strong association with viral persistence, occurred com-
monly, and as a haplotype with HLA-B*35, had been reported
to be strongly associated with more rapid HIV progression (4).
Therefore, further analyses of this allele were undertaken.
HLA-Cw*04 and HCV persistence. HLA-Cw*04 is in strong
linkage disequilibrium with the related alleles, HLA-B*53 and
HLA-B*35, with the former being more common in African-
Americans. Of these two HLA alleles, only HLA-B*5301 (OR,
1.70; 95% CI, 0.95 to 3.06) and the B*5301-Cw*04 haplotype
(OR, 1.76; 95% CI, 0.94 to 3.26) demonstrated a similar,
though not significant, relationship with persistence (Table 4).
HLA-B*5301 and the B*5301-Cw*04 haplotype were associ-
ated with persistence in Caucasians and African-Americans.
When individuals with HLA-B*5301 were excluded, the asso-
ciation with HLA-Cw*04 and HCV persistence remained (OR,
1.71; 95% CI, 1.06 to 2.75). The associations with HLA-Cw*04
could not be attributed to HIV status, since the same relation-
ships were observed when the HIV-seronegative participants
were examined separately (OR, 1.56; 95% CI, 0.98 to 2.48).
Of the 15 individuals homozygous for HLA-Cw*04, 14 were
persistently infected. A Maentel-Haenszel test for trend indi-
cated a codominant effect for HLA-Cw*04 (P  0.009); thus,
individuals with one HLA-Cw*04 allele were more likely to
have a persistent infection, while those with both alleles almost
always had a persistent infection. All four individuals homozy-
gous for HLA-B*5301, three of whom were HLA-Cw*04 ho-
mozygotes, were persistently infected; however, the Maentel-
Haenszel test for trend did not reach statistical significance
(P  0.05).
The peptide binding cleft for the class I alleles consists of
nine pockets (2). The B and F pockets, which bind the second
amino acid (P2) and the carboxyl-terminal amino acids of the
bound peptide, respectively, are the most important determi-
nants of binding specificity. Thus, we examined the alleles
which had either identical B or F binding pockets to Cw*04.
HLA-Cw*14 is the only allele identical at the B pocket, and
HLA-Cw*1801 is the only allele which shares an identical F
pocket to HLA-Cw*04. Neither of these was associated with
viral persistence (OR, 0.62 and 0.68, respectively).
We also investigated whether HLA-Cw*04 was associated
with a higher level of HCV RNA among those who were
persistently infected. The HCV RNA levels from the first spec-
imen in this study were log transformed, and the median values
in those with and without HLA-Cw*04 were determined. No
difference between the groups was observed (median of 6.6 for
both groups).
Association of HLA-B*35 and HLA-B*53 subtypes with viral
TABLE 3. HLA class I alleles that are predisposing factors to
persistence of HCV infection, stratified by ethnic group
Group and HLA
allelea
Frequency of
clearance (%)
Frequency of
persistence (%) OR (95% CI)
All participants
A*2301 3.9 6.3 1.78 (1.01–3.11)
Cw*04 9.6 15.3 1.78 (1.23–2.59)
Caucasians
A*2301 2.6 2.3 0.87 (0.32–2.41)
Cw*04 6.5 9.9 1.69 (0.91–3.15)
African-Americans
A*2301 5.9 11.3 2.24 (1.10–4.57)
Cw*04 12.9 20.7 1.69 (1.02–2.79)
a The numbers of alleles examined (n) (double the number of persons) were as
follows: for all participants, n  462 for frequency of clearance and 888 for
frequency of persistence; for Caucasians, n  234 for clearance and 438 for
persistence; for African-Americans, n  186 for clearance and 362 for persis-
tence.
TABLE 4. Association of HLA-Cw*04, Cw*04-B*35, Cw*04-B*53,
B*35-Px, and B*35-PY, stratified by ethnic group
Group and HLA allele
or haplotypea
Frequency of
clearance (%)
Frequency of
persistence (%) OR (95% CI)
All participants
Alleles
Cw*04 9.6 15.3 1.78 (1.23–2.59)
B*5301 3.5 5.8 1.70 (0.95–3.06)
B*35 7.0 7.6 1.07 (0.68–1.69)
B*35-Px 5.7 7.9 1.43 (0.89–2.29)
B*35-PY 4.8 5.4 1.11 (0.66–1.88)
Haplotypes
Cw*04-B*5301 3.1 5.2 1.76 (0.94–3.26)
Cw*04-B*35 4.8 6.5 1.36 (0.80–2.31)
Cw*04-B*35-Px 4.4 6.9 1.63 (0.97–2.76)
Cw*04-B*35-PY 3.5 4.8 1.33 (0.73–2.43)
Caucasians
Alleles
Cw*04 6.5 9.9 1.69 (0.91–3.15)
B*5301 0.4 0.7 1.82 (0.19–17.89)
B*35 6.1 7.3 1.17 (0.60–2.28)
B*35-Px 3.0 3.4 1.08 (0.42–2.73)
B*35-PY 3.5 4.6 1.31 (0.56–3.07)
Haplotypes
Cw*04-B*5301 0.4 0.7 1.82 (0.18–17.9)
Cw*04-B*35 4.4 6.4 1.41 (0.65–3.05)
Cw*04-B*35-Px 1.8 2.8 1.53 (0.48–4.82)
Cw*04-B*35-PY 3.1 4.4 1.35 (0.55–3.34)
African-Americans
Alleles
Cw*04 12.9 20.2 1.69 (1.02–2.79)
B*5301 7.5 12.7 1.77 (0.95–3.30)
B*35 8.6 5.5 0.61 (0.31–1.20)
B*35-Px 8.6 13.0 1.57 (0.87–2.85)
B*35-PY 7.5 5.2 0.67 (0.33–1.35)
Haplotypes
Cw*04-B*5301 6.5 11.3 1.84 (0.95–3.59)
Cw*04-B*35 5.4 3.9 0.69 (0.30–1.58)
Cw*04-B*35-Px 7.0 11.3 1.69 (0.88–3.24)
Cw*04-B*35-PY 4.8 3.9 0.77 (0.33–1.81)
a The numbers of alleles examined (n) (double the number of persons) were as
follows: for all participants, n  462 for frequency of clearance and 888 for fre-
quency of persistence; for Caucasians, n  234 for clearance and 438
for persistence; for African-Americans, n  186 for clearance and 362 for
persistence.
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persistence. HLA-B*53 and HLA-B*35 can be grouped accord-
ing to their binding preferences at the B and F pockets (28).
We tested the hypothesis that the HLA-B*5301 association
may be stronger if it is combined with functionally similar B*35
subtypes. In this panel of subjects, eight HLA-B*35 subtypes
and one HLA-B*53 subtype (B*5301) were identified. Based
on peptide binding preferences, the HLA-B*35 and HLA-B*53
subtypes can be divided into two groups: (i) those binding
proline at P2 and tyrosine at P9, B*35-PY (B*3501, B*3508,
and B*3517) and (ii) those binding proline at P2 but not rec-
ognizing tyrosine at P9, B*35-Px (B*3502, B*3503, B*3504,
B*3512, B*3522, and B*5301). Neither the B*35-PY group nor
the B*35-Px group were associated with HCV clearance or
persistence (OR of 1.11 and 1.43, respectively). The associa-
tion with the Cw*04-Px haplotype and viral persistence (OR,
1.63; 95% CI, 0.97 to 2.76) was similar to that of the Cw*04-
B*5301 haplotype.
Effect of heterozygosity on outcome. We also hypothesized
that individuals with greater class I allelic diversity, i.e., those
who are fully heterozygous, may be able to present a wider
array of antigens and thus be more likely to clear HCV. The
individuals who were homozygous at one locus were not more
likely to have a persistent HCV infection (OR, 1.27; 95% CI,
0.81 to 1.98) than those who were fully heterozygous. Likewise,
the individuals who were homozygous at two or three loci were
not more likely to be persistently infected (OR, 1.11; 95% CI,
0.50 to 2.47) than those who were fully heterozygous or ho-
mozygous at only one locus; however, only 28 people were
homozygous at two or three loci.
DISCUSSION
In this investigation, which is the first to examine HLA class
I alleles in the context of HCV clearance, we used the largest
known clearance panel to date with carefully matched controls.
We found that HLA-A*1101, -B*57, and -Cw*0102 were asso-
ciated with viral clearance and that HLA-A*2301 and -Cw*04
were associated with viral persistence. Detailed analysis of
HLA-Cw*04 and the alleles with which it forms haplotypes,
namely, HLA-B*35 and HLA-B*53, did not uncover an asso-
ciation stronger than with HLA-Cw*04 alone. While the bio-
logic basis for these HLA associations remains to be proven,
they cumulatively could account for outcomes in up to 18% of
the subjects in these cohorts. Thus, although class I HLA genes
are potentially important, other genes that regulate or affect
the immune response should also be examined.
The HLA-B*57 association with viral clearance was present
in both Caucasians and African-Americans. Interestingly,
HLA-B*57 has also been associated with slow progression of
HIV-1 disease in different ethnic populations (8, 15); thus, this
allele may have some protective activity in a variety of chronic
viral illnesses. Alternatively, HLA-B*57 may be in linkage dis-
equilibrium with a gene that promotes elimination of viral
infections. Finding the association of HLA-Cw*0102 with
clearance only in Caucasians is not necessarily surprising and
points to the importance of examining more than one ethnic
group. This observation suggests that HLA-Cw*0102 is either
linked to a true susceptibility gene or interacts with another
gene that is present only in Caucasians.
In this study, individuals with either HLA-Cw*04 or HLA-
B*5301, which are in strong linkage disequilibrium, had an
almost twofold-increased risk of being persistently HCV in-
fected. Despite the relatively large size of this clearance cohort,
there were too few subjects to precisely distinguish which allele
was most important. However, several pieces of evidence sug-
gest that the HLA-Cw*04 allele is the critical factor and that
the HLA-B*5301 association was present due to its linkage
disequilibrium with HLA-Cw*04. First, the relationship with
HLA-Cw*04 was present even in those without the HLA-
B*5301 allele. If HLA-B*5301 were driving the association, a
decrease in the magnitude would be expected when HLA-
B*5301-positive individuals were excluded from the analysis.
An analysis of HLA-B*5301 excluding those with HLA-Cw*04
could not be done because of the limited number of subjects
with this profile. Second, a strong codominant effect of HLA-
Cw*04 was noted, demonstrating that those with two copies of
the allele rarely eliminate the virus while those with one copy
may overcome the predisposition toward viral persistence.
Only 3 of the 14 HLA-Cw*04 homozygous individuals were
also homozygous for HLA-B*5301, which also supports an
association with HLA-Cw*04. Third, when functionally similar
subtypes of HLA-B*5301 were grouped (Px group), the asso-
ciation with persistence was not strengthened.
It is not necessarily surprising that neither of the alleles with
an identical B or F binding pocket to Cw*04 were associated
with viral persistence, since peptide binding is determined by
more than one pocket. However, if one of these alleles had also
been associated with viral persistence, then there would have
been evidence for the importance of a particular pocket in
HCV infection.
One could speculate that HLA-Cw*04 presents HCV pep-
tides that lead to an ineffective immune response or that it
interacts with the virus or another host protein that favors viral
persistence; however, data supporting such mechanisms do not
exist. Alternatively, data do support the hypothesis that the
association with HLA-Cw*04 could be linked to its putative
interaction with natural killer (NK) cells, which are important
in clearing many viral infections and may also be important in
HCV clearance (14, 17). Cw*04 behaves as a ligand for one of
the NK cell receptors among the killer immunoglobulin-like
receptor group. Unlike CTLs, NK cells are programmed to kill
the target cell unless its inhibitory receptor is engaged by a
target cell ligand such as Cw*04. It is possible that NK cells
have an important role in determining HCV clearance early in
an acute infection but are less important once a persistent
infection has been established. The association of HLA-Cw*04
with viral persistence but not with HCV RNA levels would
support this hypothesis. It is logical that NK cells may be
important for viral clearance initially, since 65% of all lympho-
cytes in the healthy, uninfected liver are NK cells or T cells that
express NK receptors (NKT cells) (9). Other viruses, such as
HIV (5), can specifically downregulate HLA-A and -B alleles,
but it is not known if HCV is capable of such immune evasion.
If it is, then the CTL response, which relies on these antigens,
may be less important for viral clearance than are NK cells. A
single study of NK cells in HCV-infected persons demon-
strated decreased NK cell activity in individuals persistently
infected with HCV than in population controls (7).
The association of HLA-Cw*04 with HCV persistence is
modest, but as recently discussed elsewhere, OR of less than
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two for individual genes are not unexpected in disease out-
comes which are multifactorial, such as HCV infection, and
may be dependent upon the presence of other genes (24). For
example, if the association of HLA-Cw*04 and HCV persis-
tence is determined by Cw*04 binding with a receptor, then the
right combination of Cw*04 and receptor would need to be
present for the effect to be seen. Such potential interactions
could be with killer immunoglobulin-like receptors or with
receptors that are yet to be described.
It seems plausible that individuals who are fully heterozy-
gous at class I alleles can present a more diverse array of
epitopes to cytotoxic T cells and thus may be more apt to clear
the virus. Although we demonstrated an association between
HLA-Cw*04 homozygosity and HCV persistence, it was sur-
prising that an overall association between class I homozygos-
ity and viral persistence was not detected. More subjects may
need to be studied to detect such an association if homozygos-
ity at two or three loci is indeed needed to see an effect.
The strengths of this study include the large clearance panel
with controls matched for factors important for viral clearance
and the rigorous class I typing methodology used. Despite
these strengths, there are a few important limitations. First, we
did not have enough power to detect associations with very low
frequency alleles. Second, due to the large number of and fairly
even distribution of class I alleles, the frequency of any indi-
vidual allele is low; thus, none of the alleles identified in this
study would be significant if we accounted for multiple com-
parisons. Thus, it is important for these associations to be
verified in other large, well-constructed cohorts and to con-
sider the biologic plausibility of these associations such as we
have done for HLA-Cw*04. Finally, causality cannot be deter-
mined by such an association study.
In summary, several HLA class I molecules are associated
with either HCV clearance or persistence supporting the im-
portance of the cytolytic T-cell response to the outcome of an
HCV infection. The association of HLA-Cw*04 with HCV
persistence and its potential relationship to innate immunity
also merit further investigation. If all the alleles found to be
associated with an HCV outcome were verified, they would still
account for only a small percentage of HCV outcomes; thus,
the search for polymorphisms in other immune regulatory
genes should continue.
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